Publications by authors named "F Spagnolo"
Background: The introduction of transcatheter procedures has focused on patient expectations for treatments with a less invasive approach and faster recovery. The aim of this study was to assess the short- and medium-term results in patients who underwent trans-axillary mitral valve repair with application of the ultra-fast-track protocol.
Methods: Data from 431 patients undergoing isolated trans-axillary mitral valve repair or associated with tricuspid valve treatment between January 2018 and December 2023 were prospectively collected.
: Dabrafenib and trametinib (D + T) have been approved for the treatment of stage III melanoma with BRAF V600E V600K mutations in an adjuvant setting, based on the results from the COMBI-AD trial. To provide early access to this combination therapy prior to its commercial availability in Italy, a Managed Access Program (MAP) was run in Italy from June 2018 to December 2019. : The MADAM (Maximing ADjuvAnt MAP) study is an Italian retrospective-prospective observational study that included patients who received at least one dose of D + T through the MAP.
View Article and Find Full Text PDFArticle Synopsis
- * Mitral valve repair was successful in 90.9% of cases, with posterior leaflet lesions showing the highest success rates, while the in-hospital mortality rate was low at 0.6%.
- * Results indicate that despite the emergence of less invasive techniques, surgical repair remains the best option for most DMR patients, with a 5-year survival rate of 95.5%.
The COVID-19 pandemic highlighted the role of indoor environments on disease transmission. However, our understanding of how transmission occurred evolved as the pandemic progressed. Enclosed spaces where pathogen-laden aerosols accumulate were strongly linked to increased transmission events.
View Article and Find Full Text PDFArticle Synopsis
- * The relationship between T2D and PAD is complex, involving factors like endothelial dysfunction and inflammation, which necessitate a focus on vascular protection, not just blood sugar control.
- * Current evidence suggests that GLP-1 receptor agonists and SGLT2 inhibitors are the most effective medications for reducing CV risk in T2D patients with PAD, with a need for personalized treatment based on individual patient history.